CoQ10 vs MitoQ
Two mitochondria-targeted antioxidants with the same pitch and very different trial records — one has a positive heart-failure mortality trial, the other one positive vascular RCT and several recent nulls.
Short answer
Neither CoQ10 nor MitoQ needs a prescription, and both have human data, so the goal decides it. CoQ10 is marketed for heart failure (as an adjunct), statin-myopathy relief, migraine prevention and general anti-aging; MitoQ is the choice for readers interested in mitochondrial antioxidant support, vascular aging and general anti-aging.
CoQ10
Coenzyme Q10, ubiquinone, ubiquinol
Q-SYMBIO showed a real reduction in cardiovascular mortality and hospitalization when added to standard heart-failure therapy — a hard outcome, not a surrogate. Migraine prevention data are real but more modest; statin-myopathy relief did not beat placebo in meta-analysis. The 'declines with age, so restore it' pitch aimed at healthy adults has no supporting outcome trial.
Full CoQ10 evidence reviewMitoQ
Mitoquinone mesylate
One real human RCT reversed vascular endothelial aging markers in healthy older adults, but the Parkinson's trial was a clean negative, and kidney-safety and exercise-redox RCTs since have also come back null — the vascular signal hasn't been shown to generalize beyond that one outcome.
Full MitoQ evidence reviewCoQ10 vs MitoQ: head to head
- FDA status / approved use
CoQ10
Sold as a supplementMitoQ
Sold as a dietary supplement; no FDA approval for any indication- Marketed for
CoQ10
Heart failure adjunct, statin-myopathy relief, migraine prevention, general anti-aging 'energy'MitoQ
Mitochondrial antioxidant support, vascular aging, general anti-aging- Outcome areas
CoQ10
Cardiovascular; Mitochondrial / cellular energy; Longevity / lifespanMitoQ
Mitochondrial / cellular energy; Cardiovascular; Longevity / lifespan- Evidence grade
CoQ10
Clinical dataMitoQ
Clinical data- How it works
CoQ10
Shuttles electrons in the mitochondrial respiratory chain and acts as an antioxidantMitoQ
CoQ10's active form linked to a cation that pulls it into mitochondria- Route and dosing
CoQ10
Oral supplement; 100 mg three times daily in the heart failure trialMitoQ
Oral capsule, 20 mg daily in most trials- Headline human result
CoQ10
Reduced major adverse cardiovascular events and mortality in chronic heart failure in the Q-SYMBIO randomized trialMitoQ
Flow-mediated dilation 42% higher vs placebo at 20 mg/day in a 2018 six-week crossover RCT of 20 older adults- Strongest evidence
CoQ10
Q-SYMBIO, JACC Heart Failure 2014CoQ10 evidence reviewPubMed 25282031MitoQ
Rossman 2018 vascular RCT, HypertensionMitoQ evidence reviewPubMed 29661838- Key safety signal
CoQ10
Well tolerated, with mostly mild gastrointestinal effects at typical dosesMitoQ
No safety signal in a 12-month trial or kidney studies; untested beyond 12 months- How it is obtained
CoQ10
Over the counter as a dietary supplementMitoQ
Over the counter as a dietary supplement
| CoQ10 | MitoQ | |
|---|---|---|
| FDA status / approved use | Sold as a supplement | Sold as a dietary supplement; no FDA approval for any indication |
| Marketed for | Heart failure adjunct, statin-myopathy relief, migraine prevention, general anti-aging 'energy' | Mitochondrial antioxidant support, vascular aging, general anti-aging |
| Outcome areas | Cardiovascular; Mitochondrial / cellular energy; Longevity / lifespan | Mitochondrial / cellular energy; Cardiovascular; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Shuttles electrons in the mitochondrial respiratory chain and acts as an antioxidant | CoQ10's active form linked to a cation that pulls it into mitochondria |
| Route and dosing | Oral supplement; 100 mg three times daily in the heart failure trial | Oral capsule, 20 mg daily in most trials |
| Headline human result | Reduced major adverse cardiovascular events and mortality in chronic heart failure in the Q-SYMBIO randomized trial | Flow-mediated dilation 42% higher vs placebo at 20 mg/day in a 2018 six-week crossover RCT of 20 older adults |
| Strongest evidence | Q-SYMBIO, JACC Heart Failure 2014CoQ10 evidence reviewPubMed 25282031 | Rossman 2018 vascular RCT, HypertensionMitoQ evidence reviewPubMed 29661838 |
| Key safety signal | Well tolerated, with mostly mild gastrointestinal effects at typical doses | No safety signal in a 12-month trial or kidney studies; untested beyond 12 months |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
CoQ10's Q-SYMBIO trial showed a real reduction in cardiovascular mortality and hospitalization in heart-failure patients — a hard outcome. MitoQ's best human result is a six-week vascular-function RCT in healthy older adults, promising but narrower, and its more recent kidney-safety and exercise-redox trials have come back null. Neither has been compared directly, and neither has outcome data supporting the general 'anti-aging energy' pitch both are sold on.
CoQ10 fits if
You have (or are managing) heart failure and want the antioxidant with an actual mortality-outcome trial behind it, discussed with your cardiologist.
MitoQ fits if
You're interested in the mitochondria-targeted-antioxidant mechanism specifically and want the one with a positive human vascular-aging RCT, understanding the evidence outside that trial is thin.
CoQ10 vs MitoQ: common questions
- Is either CoQ10 or MitoQ FDA-approved?
- No. CoQ10 is sold as a supplement. MitoQ is sold as a dietary supplement; no FDA approval for any indication.
- Which has stronger human evidence, CoQ10 or MitoQ?
- Neither clearly. Both have human clinical data. The key source for CoQ10 is Q-SYMBIO, JACC Heart Failure 2014; for MitoQ, it is Rossman 2018 vascular RCT, Hypertension.
- What are the main safety concerns with CoQ10 and MitoQ?
- CoQ10 is well tolerated, with mostly mild gastrointestinal effects at typical doses. MitoQ has no safety signal in a 12-month trial or kidney studies; untested beyond 12 months.
Key studies behind each
CoQ10
- Mortensen SA, Rosenfeldt F, Kumar A, et al. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. PubMed 25282031
- Banach M, Serban C, Sahebkar A, et al. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. PubMed 25440725
- Sandor PS, Di Clemente L, Coppola G, et al. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. PubMed 15728298
- Kalen A, Appelkvist EL, Dallner G. (1989). Age-related changes in the lipid compositions of rat and human tissues. Lipids. PubMed 2779364
MitoQ
- Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. (2001). Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. PubMed 11092892
- Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR. (2014). Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J Physiol. PubMed 24665093
- Gioscia-Ryan RA, Battson ML, Cuevas LM, Eng JS, Murphy MP, Seals DR. (2018). Mitochondria-targeted antioxidant therapy with MitoQ ameliorates aortic stiffening in old mice. J Appl Physiol. PubMed 29074712
- Rossman MJ, Santos-Parker JR, Steward CAC, Bispham NZ, Cuevas LM, Rosenberg HL, Woodward KA, Chonchol M, Gioscia-Ryan RA, Murphy MP, Seals DR. (2018). Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. Hypertension. PubMed 29661838
The full evidence reviews
- CoQ10: strong cardiac evidence, hype everywhere else
The Q-SYMBIO trial cut mortality in heart failure — but statin-muscle data are mixed, migraine support is moderate, and the anti-aging pitch rests on a decline, not an outcome.
Updated August 2026
- MitoQ: the real evidence behind the mitochondria-targeted antioxidant
A genuinely engineered delivery mechanism and one well-run human vascular trial — but a Parkinson's trial and a muscle-redox trial both came back negative.
Updated August 2026